نتایج جستجو برای: fulvestrant

تعداد نتایج: 782  

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2004
Jingyung Hur Jessica Chesnes Kathryn R Coser Roseanna S Lee Peter Geck Kurt J Isselbacher Toshi Shioda

Evidence has been accumulating that some estrogen-dependent human breast cancers require estrogen for not only proliferation but also survival. To obtain insights into the molecular mechanisms of apoptosis of breast cancer cells subjected to estrogen starvation or exposed to antiestrogens, we characterized changes in the gene expression profile of MCF-7/BUS human breast cancer cells and reveale...

2010
Mehrdad Roghani Mehdi Mafakheri Tourandokht Baluchnejadmojarad

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the co...

Journal: :The Journal of steroid biochemistry and molecular biology 2012
Eric Badia Aurélie Docquier Muriel Busson Marion Lapierre Pascal Pujol Patrick Balaguer Vincent Cavailles

Most ovarian cancers are estrogen-positive and hormonal treatments using anti-estrogens or aromatase inhibitors are under investigation for treating the tumors that are resistant to conventional therapies. In this study, the long-term effects of two anti-estrogens, namely 4-hydroxytamoxifen and fulvestrant (or ICI182,780), were investigated in ERα-positive BG1 epithelial ovarian cancer cells. T...

2014
Youn-Sang Jung Ho-Young Chun Min-Ho Yoon Bum-Joon Park

Since loss of VHL is frequently detected early phase genetic event in human renal cell carcinoma, pVHL is assumed to be indispensable for suppression of tumor initiation step. However, induction of HIF-1α, target of pVHL E3 ligase, is more adequate to angiogenesis step after tumor mass formation. Concerning this, it has been reported that pVHL is involved in centrosome location during metaphase...

Journal: :Neurobiology of learning and memory 2011
Maryam Bagheri Mohammad-Taghi Joghataei Simin Mohseni Mehrdad Roghani

Alzheimer's disease (AD) is a debilitating neurodegenerative disorder characterized by increased β-amyloid (Aβ) deposition and neuronal dysfunction leading to impaired learning and recall. Ageing, heredity, and induced oxidative stress are among proposed risk factors. The increased frequency of the disease in women also suggests a role for estrogen in development of AD. In the present study, ef...

Journal: :Molecular cancer therapeutics 2010
Yanxia Ning Rebecca B Riggins Jennifer E Mulla Haniee Chung Alan Zwart Robert Clarke

Antiestrogens are effective therapies for the management of many estrogen receptor-alpha (ER)-positive breast cancers. Nonetheless, both de novo and acquired resistance occur and remain major problems in the clinical setting. IFNgamma is an inflammatory cytokine that induces the expression and function of IFN regulatory factor 1 (IRF1), a tumor suppressor gene that can increase antiestrogen res...

Journal: :Cancer discovery 2011
Todd W Miller Justin M Balko Emily M Fox Zara Ghazoui Anita Dunbier Helen Anderson Mitch Dowsett Aixiang Jiang R Adam Smith Sauveur-Michel Maira H Charles Manning Ana M González-Angulo Gordon B Mills Catherine Higham Siprachanh Chanthaphaychith Maria G Kuba William R Miller Yu Shyr Carlos L Arteaga

Most estrogen receptor α (ER)-positive breast cancers initially respond to antiestrogens, but many eventually become estrogen-independent and recur. We identified an estrogen-independent role for ER and the CDK4/Rb/E2F transcriptional axis in the hormone-independent growth of breast cancer cells. ER downregulation with fulvestrant or small interfering RNA (siRNA) inhibited estrogen-independent ...

2017
Simon Peter Gampenrieder Gabriel Rinnerthaler Richard Greil

At the 2016 San Antonio Breast Cancer Symposium, several interesting phase II and phase III studies investigating systemic therapies for metastatic breast cancer were presented. The PrEGOC 0102 trial demonstrated that the combination of fulvestrant plus everolimus is safe and effective and could be an alternative to exemestane plus everolimus for selected patients with hormone-receptor positive...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید